early development was solely by bristol myers squibb in 2007 astrazeneca joined with bristol myers squibb to co develop the final compound and collaborate on the marketing of the drug in april 2016 the u s fda added a warning about increased risk of heart failure this was based on data in an article that concluded dpp 4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events though the rate of hospitalization for heart failure was increased although saxagliptin improves glycemic control other approaches are necessary to reduce cardiovascular risk in patients with diabetes saxagliptin is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes it does not appear to decrease the risk of heart attacks or strokes it increases the risk of hospitalization for heart failure by about 27 like other dpp 4 inhibitors it has relatively modest hba1c lowering ability is associated with a relatively low risk of hypoglycemia and does not cause weight gain saxagliptin improved mean hba1c levels relative to placebo in a 24 week trial in people with type 2 diabetes combination therapy with saxagliptin and metformin was more effective than saxagliptin or metformin